Please use this identifier to cite or link to this item: http://ir.mu.ac.ke:8080/jspui/handle/123456789/2167
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBusakhala Nafthali.-
dc.contributor.authorWaako Paul-
dc.contributor.authorChite Asirwa Fredrick-
dc.contributor.authorRobert Strother Matthew-
dc.contributor.authorKipyegon Keter Alfred-
dc.contributor.authorKimutai Kigen Gabriel-
dc.contributor.authorLoehrer Patrick J.-
dc.date.accessioned2018-11-06T06:39:22Z-
dc.date.available2018-11-06T06:39:22Z-
dc.date.issued2018-09-
dc.identifier.urihttps://doi.org/10.1200/JGO.17.00077-
dc.identifier.urihttp://ir.mu.ac.ke:8080/xmlui/handle/123456789/2167-
dc.language.isoenen_US
dc.publisherAmerican Society of Clinical Oncologyen_US
dc.subjectGemcitabineen_US
dc.subjectBleomycin Plus Vincristineen_US
dc.subjectKaposi’s Sarcomaen_US
dc.subjectAntiretroviral Therapyen_US
dc.titleRandomized Phase IIA Trial of Gemcitabine Compared With Bleomycin Plus Vincristine for Treatment of Kaposi’s Sarcoma in Patients on Combination Antiretroviral Therapy in Western Kenyaen_US
dc.typeArticleen_US
Appears in Collections:School of Medicine

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.